Discontinuation of Sotacor® Ampoules

HPS Pharmacies wish to advise that Aspen Pharma has given notice of the discontinuation of:

Sotacor® Ampoules 
Sotalol hydrochloride 40mg/4mL
ARTG 54089
.

Sotalol is a non-selective beta-blocker with class III anti-arrhythmic properties. It is indicated for the prevention and treatment of supraventricular and ventricular arrhythmias. While the ampoules are no longer available, sotalol will continue to be available as an oral preparation. Oral sotalol has an absolute bioavailability of close to 100% and is often the preferred method of administering sotalol. However, peak plasma levels may not be reached until two to three hours after an oral dose.

Therapeutic alternatives for intravenously administered sotalol will depend upon the indication and patient characteristics. The Australian Resuscitation Council publish guidelines for the management of acute dysrhythmias. Alternative therapies should be discussed with a cardiologist.

Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Aspen Pharma on 1300 659 646.

References:

  1. Sotacor® (sotalol hydrochloride) Australian approved product information. Melbourne: Aspen Pharma. Approved March 2010.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates